2-(bis(4-methoxyphenyl)(phenyl)methoxy)ethanamine | 153765-10-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: 2-(bis(4-methoxyphenyl)(phenyl)methoxy)ethanamine
• 英文别名: 2-[Bis(4-methoxyphenyl)phenylmethoxy]ethanamine；2-[bis(4-methoxyphenyl)-phenylmethoxy]ethanamine
• CAS: 153765-10-7
• 化学式: C₂₃H₂₅NO₃
• 分子量: 363.456
• InChiKey: DDTMRVIKRYMFGU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  27
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  53.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(bis(4-methoxyphenyl)(phenyl)methoxy)ethanamine 在 N-甲基吗啉 、 4-甲氧基吡啶-N-氧化物 、 2,4,6-三异丙基苯磺酰氯 、 水 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 乙酸乙酯 、 N,N-二甲基甲酰胺 、 甲苯 、 乙腈 为溶剂， 反应 4.5h， 生成 ({{2-[Bis-(4-methoxy-phenyl)-phenyl-methoxy]-ethyl}-[2-(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-acetyl]-amino}-methyl)-phosphonic acid mono-(4-methoxy-1-oxy-pyridin-2-ylmethyl) ester
  参考文献：
  名称：

  包含N -2-羟乙基-氨基甲基膦酸酯骨架的低聚物的合成方法：新型PNA类似物

  摘要：

  制备4-甲氧基-1-氧化吡啶-2-甲基N -2-（4,4'-二甲氧基三苯甲氧基）乙基-N-胸腺嘧啶-1-基-氨基甲基膦酸酯（1a，T ∗）和报道了相应的N 4-苯甲酰基胞嘧啶-1-基衍生物1b（C ∗）。这些PPNA单体被证明是固相合成十四聚体片段的基础材料（C * T * T * T * T * C * T * T * T * T * C * T *C ∗ T ∗）dT。

  DOI：

  10.1016/0040-4039(96)01750-9
• 作为产物：
  描述：

  2-(2-(bis(4-methoxyphenyl)(phenyl)methoxy)ethyl)isoindoline-1,3-dione 在 一水合肼 作用下， 以 甲醇 为溶剂， 生成 2-(bis(4-methoxyphenyl)(phenyl)methoxy)ethanamine
  参考文献：
  名称：

  用于制备3'-氨基修饰的寡核苷酸的新型氨基甲酸酯载体。

  摘要：

  描述了一种制备在3'-末端带有氨基的寡核苷酸的新颖方法。使用两种不同的策略制备了具有氨基烷基和通过碱不稳定的氨基甲酸酯键如2-（2-硝基苯基）乙氧基羰基和芴基甲氧基羰基连接的3'-氨基-2'，3'-二脱氧核苷的几种CPG载体。这些支持物与标准的固相亚磷酸三酯方法兼容，并产生在3'端含有氨基的寡核苷酸。讨论了3'-氨基寡核苷酸的几种特性，例如核酸酶抗性，杂交和寡核苷酸缀合物的制备。

  DOI：

  10.1016/0968-0896(96)00156-3

文献信息

• ORGANIC COMPOUNDS TO TREAT HEPATITIS B VIRUS
  申请人：Baryza Jeremy Lee

  公开号：US20160215288A1

  公开（公告）日：2016-07-28

  The disclosure relates to compositions comprising a HBV RNAi agent. In some embodiments, the HBV RNAi agent comprises a sense and an anti-sense strand, each strand being an 18-mer and the strands together forming a blunt-ended duplex, wherein the 3′ end of at least one strand terminates in a phosphate or modified internucleoside linker and further comprises, in 5′ to 3′ order: a spacer; a second phosphate or modified internucleoside linker; and a 3′ end cap. In some embodiments, the 3′ end of both the sense and anti-sense strand further comprise, in 5′ to 3′ order: a spacer; a second phosphate or modified internucleoside linker; and a 3′ end cap. The two strands can have the same or different spacers, phosphates or modified internucleoside linkers, and/or 3′ end caps. The strands can be ribonucleotides, or, optionally, one or more nucleotide can be modified or substituted. Optionally, at least one nucleotide comprises a modified internucleoside linker. Optionally, the RNAi agent can be modified on one or both 5′ end. Optionally, the sense strand can comprise a 5′ end cap which reduces the amount of the RNA interference mediated by this strand. Optionally, the RNAi agent is attached to a ligand. This format can be used to devise RNAi agents to a variety of different targets and sequences. The disclosure also relates to processes for making such compositions, and methods and uses of such compositions, e.g., to mediate RNA interference. The disclosure also pertains to methods of treating, ameliorating and preventing HBV in a patient involving the step of administering to the patient a therapeutic amount of a HBV RNAi agent.

  该披露涉及包含HBV RNAi药剂的组合物。在某些实施例中，HBV RNAi药剂包括一个正义链和一个反义链，每个链都是18个核苷酸长，并且这些链一起形成一个带有钝端的双链，其中至少一个链的3'端终止于磷酸酯或修饰的核苷酸间连接物，并且进一步包括，按照5'到3'的顺序：一个间隔物；第二个磷酸酯或修饰的核苷酸间连接物；和一个3'端帽。在某些实施例中，正义链和反义链的3'端进一步包括，按照5'到3'的顺序：一个间隔物；第二个磷酸酯或修饰的核苷酸间连接物；和一个3'端帽。这两个链可以具有相同或不同的间隔物、磷酸酯或修饰的核苷酸间连接物，和/或3'端帽。这些链可以是核糖核苷酸，或者，可选地，一个或多个核苷酸可以被修饰或替代。可选地，至少一个核苷酸包括一个修饰的核苷酸间连接物。可选地，RNAi药剂可以在一个或两个5'端上被修饰。可选地，正义链可以包括减少由该链介导的RNA干扰量的5'端帽。可选地，RNAi药剂附着在一个配体上。这种格式可以用来设计针对各种不同靶标和序列的RNAi药剂。该披露还涉及制备这种组合物的方法，以及这种组合物的方法和用途，例如，用于介导RNA干扰。该披露还涉及涉及将治疗量的HBV RNAi药剂给患者的步骤来治疗、改善和预防患者体内的HBV的方法。
• [EN] TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS<br/>[FR] COMPOSITIONS DE CONJUGUÉS D'ACIDES NUCLÉIQUES CIBLÉS
  申请人：PROTIVA BIOTHERAPEUTICS INC

  公开号：WO2017177326A1

  公开（公告）日：2017-10-19

  The invention provides conjugates that comprise a targeting moiety, a nucleic acid, and optional linking groups as well as synthetic intermediates and synthetic methods useful for preparing the conjugates. The conjugates are useful to target therapeutic nucleic acids to the liver and to treat liver diseases including hepatitis (e.g. hepatitis B and hepatitis D).

  这项发明提供了包括靶向基团、核酸和可选连接基团的共轭物，以及用于制备这些共轭物的合成中间体和合成方法。这些共轭物可用于将治疗性核酸靶向肝脏，并用于治疗包括肝炎（如乙型肝炎和丙型肝炎）在内的肝脏疾病。
• MELANIN PRODUCTION INHIBITOR
  申请人：Yokoyama Kouji

  公开号：US20110243865A1

  公开（公告）日：2011-10-06

  Disclosed is a melanin production inhibitor which has an excellent inhibitory activity on the production of melanin and is highly safe. The melanin production inhibitor comprises a compound represented by general formula (1) (excluding clotrimazole), and/or a pharmacologically acceptable salt thereof. In the formula, A1, A2 and A3 are independently selected from a hydrogen atom, an aryl group which may have a substituent, and an aromatic heterocyclic group which may have a substituent, wherein at least one of A1, A2 and A3 is selected from the aryl group and the aromatic heterocyclic group, the total number of carbon atoms contained in A1, A2 and A3 is 6 to 50 and, when at least two of A1, A2 and A3 represent the aryl groups or the aromatic heterocyclic groups, the adjacent two aryl or aromatic heterocyclic groups may be bound to each other via an alkyl chain or an alkenyl chain to form a ring; m represents an integer of 0 to 2; X represents a hetero atom, a hydrogen atom, or a carbon atom; R1 and R2 are independently selected from a hydrogen atom and an oxo group, wherein when one of R1 and R2 is an oxo group, the other is not present; and R3 is selected from a hydrogen atom, and a C 1-8 hydrocarbon group in which one or some of hydrogen atoms or carbon atoms may be substituted by a hetero atom or hetero atoms, wherein the number of R3's present in the compound corresponds to the number of X's and, when two or more R3's are present, the R3's are independently present and the adjacent two R3's may be bound to each other to form, together with X, a ring, and the terminal of R3 may be bound to a carbon atom to which A1, A2 and A3 are bound, thereby forming a ring.

  披露了一种黑色素生产抑制剂，它对黑色素的生产具有出色的抑制活性且高度安全。该黑色素生产抑制剂包括由通用公式（1）表示的化合物（不包括克霉唑）和/或其药理上可接受的盐。在公式中，A1、A2和A3独立地选自氢原子、可能带有取代基的芳基团和可能带有取代基的芳香杂环团，其中至少A1、A2和A3之一选自芳基团和芳香杂环团，A1、A2和A3中包含的碳原子总数为6至50，并且当至少两个A1、A2和A3表示芳基团或芳香杂环团时，相邻的两个芳基或芳香杂环团可以通过烷基链或烯基链相互连接形成环；m代表0至2的整数；X代表异原子、氢原子或碳原子；R1和R2独立地选自氢原子和氧代基，其中当R1和R2之一是氧代基时，另一个不出现；R3选自氢原子和C 1-8 碳氢化合物组，其中一些或所有的氢原子或碳原子可能被异原子或异原子取代，其中化合物中存在的R3的数量对应于X的数量，并且当存在两个或更多R3时，R3独立地存在，并且相邻的两个R3可以相互连接以与X一起形成环，并且R3的末端可以与A1、A2和A3连接的碳原子结合，从而形成环。
• New carbamate supports for the preparation of 3′-amino-modified oligonucleotides
  作者：Anna Aviñó、Ramon Güimil Garcia、Fernando Albericio、Matthias Mann、Matthias Wilm、Gitte Neubauer、Ramon Eritja

  DOI：10.1016/0968-0896(96)00156-3

  日期：1996.10

  A novel approach for the preparation of oligonucleotides carrying amino groups at the 3'-end is described. Several CPG supports having aminoalkyl groups and 3'-amino-2',3'-dideoxynucleosides linked through base-labile carbamate linkages such as 2-(2-nitrophenyl)ethoxycarbonyl and fluorenylmethoxycarbonyl were prepared using two different strategies. These supports are compatible to the standard solid

  描述了一种制备在3'-末端带有氨基的寡核苷酸的新颖方法。使用两种不同的策略制备了具有氨基烷基和通过碱不稳定的氨基甲酸酯键如2-（2-硝基苯基）乙氧基羰基和芴基甲氧基羰基连接的3'-氨基-2'，3'-二脱氧核苷的几种CPG载体。这些支持物与标准的固相亚磷酸三酯方法兼容，并产生在3'端含有氨基的寡核苷酸。讨论了3'-氨基寡核苷酸的几种特性，例如核酸酶抗性，杂交和寡核苷酸缀合物的制备。
• METHOD AND APPARATUS FOR COMBINATORIAL CHEMISTRY
  申请人：Foote Robert S.

  公开号：US20100010209A1

  公开（公告）日：2010-01-14

  A method and apparatus are provided for performing light-directed reactions in spatially addressable channels within a plurality of channels. One aspect of the invention employs photoactivatable reagents in solutions disposed into spatially addressable flow streams to control the parallel synthesis of molecules immobilized within the channels. The reagents may be photoactivated within a subset of channels at the site of immobilized substrate molecules or at a light-addressable site upstream from the substrate molecules. The method and apparatus of the invention find particularly utility in the synthesis of biopolymer arrays, e.g., oligonucleotides, peptides and carbohydrates, and in the combinatorial synthesis of small molecule arrays for drug discovery.

  提供了一种方法和装置，用于在多个通道内的可空间寻址通道中执行光导向反应。发明的一个方面利用了在溶液中的光活化试剂，将其置于可空间寻址的流动通道中，以控制通道内固定分子的并行合成。这些试剂可以在固定底物分子的通道子集内或在底物分子上游的光可寻址位置处进行光活化。该发明的方法和装置在生物聚合物阵列的合成中特别有用，例如寡核苷酸、肽和碳水化合物，以及用于药物发现的小分子阵列的组合合成。